A federal regulatory crackdown on Hims could impact a broader network of compounding pharmacies and telehealth companies.

Hims & Hers stock (NYSE: HIMS) increased by 16% yesterday following its announcement about expanding into the treatment of menopause and perimenopause—a strategic shift indicating that the company is ...

CHONGQING, CHINA - JULY 30: In this photo illustration, a person holds a smartphone displaying the logo of Hims & Hers Health Inc. (NYSE: HIMS), an American telehealth company offering personal care ...

Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. The company is building a moat through personalized medicine, vertical integration, and diversification ...

Few people consult a doctor before attempting weight loss. Hims offers virtual weight loss support for men, including consultations and prescriptions. Hims provides GLP-1 injections, meal replacements ...

HIMS is upgraded to a speculative Buy after the steep correction, with the cheaper valuations offering a much-needed, improved margin of safety. Robust subscription/ARPU growth, international ...

Hims & Hers Health, Inc. HIMS is scheduled to report second-quarter 2025 results on Aug. 4, after the closing bell. In the last reported quarter, the company’s earnings per share (EPS) of 20 cents ...